Literature DB >> 29368083

Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.

Ibrahim Kulac1,2, Sehbal Arslankoz1, George J Netto3, Dilek Ertoy Baydar4.   

Abstract

Non-invasive low-grade papillary urothelial carcinoma (NILGPUC) of the bladder is regarded as a relatively indolent disease. However, its propensity for frequent recurrences constitutes a major clinical problem. Additionally, there is a progression risk of 10-15% to either a higher grade and/or a higher stage disease in these tumors. The molecular factors that will predict recurrence and progression in low-grade pTa bladder carcinoma have not yet been elucidated. Herein, we investigated the association of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) alterations with recurrence and progression in NILGPUC using immunohistochemistry. Eighty-one cases of bladder cancer initially diagnosed as NILGPUC in a single institution with follow-up were encountered after searching medical records. Tissue microarrays (TMA) that contained both tumor and non-neoplastic mucosa from each case were constructed using paraffin blocks of transurethral resections. Sections from TMA blocks were stained immunohistochemically for PTEN protein and were evaluable in 76 cases. Any absence of staining was recorded and correlated with clinical findings. Ten patients (13.2%) showed progression and 41 (53.9%) showed recurrence. Reduced PTEN expression was observed in 29 cases (38.1%). Cases with reduced PTEN had higher progression rate compared to cases with intact PTEN (p = 0.026). Tumor relapse was more frequent in cases with reduced PTEN (65.5 vs 46.8%), but this difference was not statistically significant (p = 0.112). On the other hand, decreased PTEN expression was associated with higher number of recurrence episodes (p = 0.002). PTEN seems to have a link with the disease course in NILGPUC of the bladder.

Entities:  

Keywords:  Bladder; Bladder cancer; Non-invasive; PTEN; Urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29368083     DOI: 10.1007/s00428-018-2302-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.

Authors:  Hiroshi Miyamoto; Fadi Brimo; Luciana Schultz; Huihui Ye; Jeremy S Miller; Daniel A Fajardo; Thomas K Lee; Jonathan I Epstein; George J Netto
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

Review 2.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

3.  Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Authors:  Chih-Hao Sun; Yen-Hwa Chang; Chin-Chen Pan
Journal:  Histopathology       Date:  2011-06       Impact factor: 5.087

4.  Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Authors:  Luciana Schultz; Roula Albadine; Jessica Hicks; Sana Jadallah; Angelo M DeMarzo; Ying-Bei Chen; Matthew E Nielsen; Matthew E Neilsen; Mark L Gonzalgo; David Sidransky; Mark Schoenberg; George J Netto
Journal:  Cancer       Date:  2010-10-11       Impact factor: 6.860

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.

Authors:  Makito Miyake; Kokichi Sugano; Hitomi Sugino; Kazuho Imai; Eri Matsumoto; Koshi Maeda; Shinich Fukuzono; Hiroki Ichikawa; Kiyotaka Kawashima; Kaoru Hirabayashi; Tetsuro Kodama; Hiroyuki Fujimoto; Tadao Kakizoe; Yae Kanai; Kiyohide Fujimoto; Yoshihiko Hirao
Journal:  Cancer Sci       Date:  2009-09-01       Impact factor: 6.716

7.  Inactivation of p53 and Pten promotes invasive bladder cancer.

Authors:  Anna M Puzio-Kuter; Mireia Castillo-Martin; Carolyn W Kinkade; Xi Wang; Tian Huai Shen; Tulio Matos; Michael M Shen; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  Genes Dev       Date:  2009-03-04       Impact factor: 11.361

8.  Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Authors:  Bojana Djordjevic; Bryan T Hennessy; Jie Li; Bedia A Barkoh; Rajyalakshmi Luthra; Gordon B Mills; Russell R Broaddus
Journal:  Mod Pathol       Date:  2012-02-03       Impact factor: 7.842

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.

Authors:  Hiroaki Kobayashi; Eiji Kikuchi; Shuji Mikami; Takahiro Maeda; Nobuyuki Tanaka; Akira Miyajima; Ken Nakagawa; Mototsugu Oya
Journal:  BMC Urol       Date:  2014-01-08       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.